Skip to content
Comparisons

LunaRx vs. Hims: GLP-1 Telehealth Compared

How LunaRx's compounded, physician-directed program stacks up against Hims' GLP-1 offering — pricing, formulations, and support.

9 min readWritten and fact-checked against the sources below
Two plain white shipping boxes on an entryway table

Disclosure

The GLP Journal is published by LunaRx, so this comparison is written with that conflict disclosed. We aim for accuracy, not advocacy. Compounded GLP-1s are prepared by licensed 503A and 503B compounding pharmacies. This is not medical advice.

LunaRx and Hims both offer GLP-1 weight care through telehealth, but they are built for different goals. Hims is a large, app-first consumer brand that sells a wide range of health products; LunaRx is a focused, physician-directed program built around one outcome — losing fat while protecting muscle, with a plan to come off. This guide lays out the honest side-by-side so you can match the model to what you actually want.

Both connect you with a licensed provider and, if appropriate, a compounded GLP-1 from a licensed pharmacy. The differences show up in the care model, what is included in the protocol, how pricing is structured, and whether there is a plan for the end — not just the start.

LunaRx vs Hims at a glance
LunaRxHims
FocusRecomposition — lose fat, keep muscleBroad consumer health, weight included
Care modelPhysician-directed, plan calibrated to youApp-first consumer telehealth
MedicationsSemaglutide or tirzepatideGLP-1 options vary by state and availability
Muscle protectionMuscle-protective peptides built into the stackNot a stated focus
Coming-off planStructured off-ramp / taper, central to the modelNot emphasized
PricingFlat, dose-independent — $139/mo semaglutide, $149/mo tirzepatideVaries by plan and dose; check current pricing
If not approved$0 — you only pay if a physician approvesCheck current policy
LanguagesEnglish and Spanish, intake to taperPrimarily English
SupplyCompounded, via licensed 503A and 503B pharmaciesCompounded and/or brand, varies by state

How the care models differ

Hims is built for scale and convenience: a familiar consumer brand, a polished app, and a broad catalog that spans hair, skin, sexual health, and weight. GLP-1 care is one line in a large menu. LunaRx does one thing — metabolic recomposition — and builds the whole experience around it. A licensed physician reviews your intake and calibrates a plan to you, and the same clinical thread runs from your first assessment through your taper.

Neither model is better in the abstract. If you want a big brand and one-stop convenience, breadth is the draw. If you want a focused program where the plan is titrated to your physiology and someone is thinking about the end from day one, depth is the draw.

What is actually in the protocol

This is the clearest practical difference. A standard GLP-1 program prescribes the medication and titrates the dose. LunaRx pairs the GLP-1 with muscle-protective peptides and recovery support, because a real share of the weight lost on a GLP-1 alone can be lean muscle. The goal is that what you lose is fat and what stays is strength — recomposition, not just a lower number on the scale.

Pricing: what you will actually pay

LunaRx uses flat, dose-independent pricing — $139/month for the semaglutide protocol and $149/month for the tirzepatide protocol as of 2026 — so your cost does not climb as you titrate up. Many consumer programs price by plan tier or dose, which means the advertised starting price is not always what you pay in month three. When you compare, compare the total monthly cost at your expected dose, including shipping and any add-ons, and confirm current pricing on each service's own page.

The coming-off question

Most platforms are built around the refill. LunaRx is built around the exit: a structured taper paired with GI-recovery and metabolic-reset support, so you can come off without the rebound that follows an abrupt stop. If how do I eventually get off this matters to you, it is a first-class part of the LunaRx model rather than an afterthought.

Where Hims may fit better

If you already use Hims for other products and value keeping everything under one familiar brand, or you simply want the most recognizable app-first option, Hims is a reasonable pick. Breadth and brand are real advantages for some people. Verify what GLP-1 product you would actually receive and the total cost before deciding.

Who LunaRx is for

  • You want to keep your muscle, not just lose weight.
  • You want a physician-directed plan calibrated to you, not a one-size template.
  • You want a real plan to come off — a taper, not an open-ended subscription.
  • You want flat pricing that will not rise as your dose does.
  • You want care in English or Spanish.

Want this handled for you?

LunaRx — clinician-led GLP-1 care with a plan to come off

LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.

Start the 2-minute eligibility checkIndependent site · by LunaRx · not medical advice

What to verify with LunaRx and Hims

  • Is this a compounded or a branded product? If compounded, which licensed 503A or 503B pharmacy prepares it, and is it properly licensed? Compounding compliance rests with the dispensing pharmacy.
  • Total monthly cost at your expected dose, including shipping and any fees.
  • Whether muscle-protective support is included or extra.
  • What happens to your plan and price if you stop.

Common questions about LunaRx vs Hims

What is the main difference between LunaRx and Hims?
LunaRx is a focused, physician-directed recomposition program — it pairs a GLP-1 with muscle-protective peptides and builds in a structured off-ramp. Hims is a broad, app-first consumer health brand where GLP-1 care is one of many services.
Which is cheaper, LunaRx or Hims?
It depends on your dose. LunaRx uses flat pricing — $139/month for semaglutide and $149/month for tirzepatide as of 2026 — that does not rise as you titrate up. Consumer programs often vary by plan or dose, so compare the total monthly cost at your expected dose and confirm current pricing on each site.
Do LunaRx and Hims sell compounded GLP-1s?
LunaRx dispenses compounded GLP-1s via licensed 503A and 503B compounding pharmacies. Hims offers compounded and/or brand depending on the state. Ask each service what product you would receive and which licensed pharmacy fills it.
Does either help you keep muscle?
LunaRx builds muscle-protective peptides into the protocol specifically to reduce lean-mass loss during weight loss. A standard GLP-1 program typically prescribes the medication alone. Ask whether muscle support is included.
Does either help you come off the medication?
LunaRx makes a structured taper central to the model. Coming-off support is not a stated emphasis of most consumer programs, so ask what the plan is for the end, not just the start.
How do I get started with LunaRx?
Complete a short online eligibility check in English or Spanish. A licensed physician reviews it and approves or denies treatment. You are only charged if you are approved.

Bottom line

Hims is broad, brand-forward, and convenient; LunaRx is a focused, physician-directed recomposition program with muscle-protective peptides, flat pricing, and a built-in off-ramp. If you want a familiar one-stop app, Hims fits. If you want to lose fat, keep muscle, and come off on a plan, that is what LunaRx is built for. We disclose that we publish this comparison — verify pricing and fit for your situation.

Sources

Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.

  1. 1.
    FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize

    U.S. Food and Drug Administration · 2025

    Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.

  2. 2.
    Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A

    U.S. Food and Drug Administration, guidance for industry · 2018

    A 503A pharmacy may not compound, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. Patient-specific compounding remains possible where the prescriber documents a clinically significant difference for that patient.

  3. 3.
    FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

    U.S. Food and Drug Administration · 2026

    April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.

Get the weekly research update

New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.

Unsubscribe anytime. Read our privacy policy.

Related in Comparisons